Angiotensin Antagonists

References

• Waeber B, Nussberger J, Brunner H R. Angiotensin converting enzyme inhibitors in hypertension. Hypertension: Pathophysiology, Diagnosis and Management, J H. Laragh, B M. Brenner. Raven Press, New York 1990; 2209–2232
   Google Scholar
• McAreavy D, Robertson J IS. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990; 40: 326–345
   Google Scholar
• Unger T, Gohlke P. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. Cardiovasc Res 1994; 28: 146–158
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–1435
   PubMed Web of Science ®Google Scholar
• Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–1456
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. The effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302
   PubMed Web of Science ®Google Scholar
• Carini D J., Duncia J V., Aldrich P E., Chiu A T., Johnson A L., Pierce M E., Price W A., Santella J B., Wells G J., Wexler R R., Wong P C., Yoo S E. Timmermans PBMWM. Non-peptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylmethyl) imidazoles as potent orally active antihypertensives. J Med Chem 1991; 34: 2525–2547
   PubMed Web of Science ®Google Scholar
• Keenan R M., Weinstock J, Finkelstein J A., Franz R G., Gaitanopoulous D E., Girard G R., Hill D T., Morgan T M., Samanen J M., Peishoff C E., Tucker L M., Aiyar N, Griffin E, Ohlstein E H., Stack E J., Weidley E F., Edwards R M. Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl) imidazole-5-acrylic acids. J Med Chem 1993; 36: 1880–1892
   Google Scholar
• Kubo K, Kohara Y, Imamiya E, Sigiura Y, Inada Y, Furukawa Y, Nishikawa K, Naka T. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J Med Chem 1993; 36: 2182–2195
   PubMed Web of Science ®Google Scholar
• Judd D B., Dowle M D., Middlemiss D, Scopes D IC, Ross B C., Jack T I., Pass M, Tranquillini E, Hobson J E., Panchal T A., Stuart P G., Paton J MS, Hubbard T, Hilditch A, Drew G M., Robertson M J., Clark K L., Travers A, Hunt A AE, Polley J, Eddershaw P J., Bayliss M K., Manchee G R., Donnelly M D., Walker D G., Richards S A. Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR 138950, a potent antihypertensive agent with high oral bioavailability. J Med Chem 1994; 37: 3108–3120
   PubMedGoogle Scholar
• Wexler R R., Greenlee W J., Irvin J D., Goldberg M R., Prendergast K, Smith R D. Timmermanns PBMWM. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 1996; 39(3)625–656
   PubMed Web of Science ®Google Scholar
• Mantlo N B., Chakravarty P K., Ondeyka D I., Seigl P KS, Chang R S., Lotti V J., Faust K A., Chen T-B, Schorn T W., Sweet C S., Emmert S E., Patchett A A., Greenlee W J. Potent, orally active imidazo (4,5-b>) pyridine-based angiotensin II receptor antagonists. J Med Chem 1991; 34: 2919–2922
   PubMed Web of Science ®Google Scholar
• Ferrario C M. Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension. Drugs 1990; 39(Suppl 2)l–8
   Google Scholar
• Vallotton M B. The renin-angiotensin system. Trends Pharmacol Sci 1987; 8: 69–74
   Web of Science ®Google Scholar
• Johnston C I. Biochemistry and pharmacology of the renin-angiotensin system. Drugs 1990; 39(1)21–31
   Google Scholar
• Lippoldt A, Paul M, Fuxe K, Ganten D. The brain renin-angiotensin system: molecular mechanism of cell to cell interactions. Clin Exp Hypertension 1995; 17: 251–266
   PubMed Web of Science ®Google Scholar
• Laragh J H. The renin system and new understanding of the complications of hypertension and their treatment. Arzneim Forsch Drug Res 1993; 43: 247–254
   PubMedGoogle Scholar
• Braunwald E. ACE inhibitors: a cornerstone of the treatment of heart failure. N Engl J Med 1991; 325: 351–353
   PubMed Web of Science ®Google Scholar
• Goldfarb D A. The renin-angiotensin system: new concepts in regulation of blood pressure and renal function. Urol Clin North Am 1994; 21: 187–194
   Google Scholar
• Unger T, Gohlke P. ACE inhibition in the tissues. Clin Physiol Biochem 1992; 9(3)89–93
   Google Scholar
• Paul M, Bachmann J, Ganten D. The tissue renin-angiotensin systems in cardiovascular disease. Trends Cardiovasc Med 1992; 2(3)94–99
   Google Scholar
• Cody R J. Renin system inhibition. Beginning the fourth epoch. Circulation 1992; 85(l)362–364
   Google Scholar
• Kleinert H D. Recent developments in renin inhibitors. Exp Opin Invest Drugs 1994; 3(11)1087–1104
   Google Scholar
• Lin C, Frishman W H. Renin inhibition: a novel therapy for cardiovascular disease. Am Heart J 1996; 131(5)1024–1034
   Google Scholar
• Pals D T., Masucci F D., Denning G S., Sipos F, Fessler D C. Role of the pressor action of angiotensin II in experimental hypertension. Circ Res 1971; 29: 673–681
   PubMed Web of Science ®Google Scholar
• Campbell W B., Pettinger W A. Organ specificity of angiotensin II and des-aspartyl angiotensin II in the conscious rat. J Pharmacol Exp Ther 1976; 198: 450–456
   PubMed Web of Science ®Google Scholar
• Blair-West J R., Coghlan J P., Denton D A., Funder J W. The effect of the hepta-peptide (2–8) and hexapeptide (3–8) fragments of angiotensin II on aldosterone secretion. J Clin Endocrinol Metab 1971; 32: 575–578
   PubMed Web of Science ®Google Scholar
• Freeman R H., Davis J O., Lohmeier T E. Des-1-Asp-Angiotenisn II: possible intrarenal role in hemostasis in the dog. Circ Res 1975; 37: 30–34
   PubMed Web of Science ®Google Scholar
• Goodfriend T L., Peach M J. Angiotensin III: (Des-aspartic acid)-angiotensin II. Evidence and speculation for its role as an important agonist in the renin-angiotensin system. Circ Res 1975; 37: 138–147
   Google Scholar
• Carey R M., Vaughan E D., Peach M J., Ayers C R. Activity of [des-Aspartyl1]-angiotensin II in man: differences in blood pressure and adrenocortical responses. J Clin Invest 1978; 61: 20–31
   PubMed Web of Science ®Google Scholar
• Moore A F., Hall M M., Khairallah P A. A comparison of the effects of angiotensin II and heptapeptide on smooth muscle (vascular and uterine). Eur J Pharmacol 1976; 39: 101–107
   Google Scholar
• Trachte G J., Peach M J. A potent noncompetitive angiotensin II antagonist induces only competitive inhibition of angiotensin III receptors. J Cardiovasc Pharmacol 1983; 5: 1025–1033
   Google Scholar
• Peach M J., Dostall D E. The angiotensin II receptor and the actions of angiotensin II. J Cardiovasc Pharmacol 1990; 16: S25–S30
   PubMed Web of Science ®Google Scholar
• Douglas J G. Angiotensin receptor subtypes of the kidney cortex. Am J Physiol 1987; 253(1)F1–F7, part 2
   Google Scholar
• Crack B E., Pollard C E., Beukers M W., Roberts S, Hunt S F., Ingall A H., McKechnie K CW, Uzerman A P., Leff P. Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase. Br J Pharmacol 1995; 114: 475–481
   PubMed Web of Science ®Google Scholar
• Furchgott R F. The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. Catecholamines. Handbook Exp. Pharmacol, H Blaschko, E Muscholl. Springer-Verlag, Berlin 1972; 283–335
   Google Scholar
• Robertson M J., Cunoosamy M P., Clark K L. Effects of peptidase inhibition on angiotensin receptor agonist and antagonist potency in rabbit isolated thoracic aorta. Br J Pharmacol 1992; 106: 166–172
   Google Scholar
• Chang R SL, Lotti V J. Selective ligands reveal subtypes of angiotensin receptors in rat vasculature and brain. Pharmacologist 1989; 31(3)150, (abstract 183)
   Google Scholar
• Chang R SL, Lotti V J. Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. Mol Pharmacol 1990; 29: 347–351
   Google Scholar
• Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 163(1)284–291
   PubMed Web of Science ®Google Scholar
• Bumpus F M., Catt K J., Chiu A T., DeGasparo M, Goodfriend T, Husain A, Peach M J., Taylor D G. Timmermans PBMWM. Nomenclature for angiotensin receptors. Hypertension 1991; 17: 720–721
   PubMed Web of Science ®Google Scholar
• Dudley D T., Panek R T., Major T C., Lu G H., Bruns R F., Klinkefus B A., Hodges J C., Weishaar R E. Subclasses of angiotensin II binding sites and their functional significance. Mol Pharmacol 1990; 38: 370–377
   PubMed Web of Science ®Google Scholar
• Van Atten M K., Ensinger C L., Chiu A T., McCall D E., Nguyen T T., Wexler R R. Timmermans PBMWM. A novel series of selective non-peptide inhibitors of angiotensin II binding to the AT2 site. J Med Chem 1993; 36(25)3985–3992
   PubMedGoogle Scholar
• Klutchko S, Hamby J M., Hodges J C. Tetrahydroisoquinoline derivatives with AT2 specific angiotensin II receptor binding inhibitory activity. Bioorg Med Chem Lett 1993; 3: 2023–2028
   Google Scholar
• Glinka T W., de Laszlo S E., Tran J, Chang R S., Chen T B., Lotti V J., Greenlee W J. L-161, 638: a potent AT2 selective quinazolinone angiotensin II binding inhibitor. Bioorg Med Chem Lett 1994; 4: 1479–1484
   Web of Science ®Google Scholar
• Brechler V, Levens N R., DeGasparo M, Bottari S P. Angiotensin AT2 receptor mediated inhibition of particulate guanylate cyclase: a link with protein tyrosine phosphatase stimulation?. Receptors Channels 1994; 2(2)79–87
   Google Scholar
• Nahmias C, Strosberg A D. The angiotensin AT2 receptor: searching for signal-transduction pathways and physiological function. Trends Pharmacol Sci 1995; 16: 223–225
   PubMed Web of Science ®Google Scholar
• Grady E F., Sechi L A., Griffin C A., Schambelan M, Kalinyak J E. Expression of AT2 receptors in the developing rat fetus. J Clin Invest 1991; 88(3)921–933
   PubMedGoogle Scholar
• Janiak P, Pillon A, Prost J F., Vilaine J P. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992; 20: 737–745
   PubMed Web of Science ®Google Scholar
• Viswanathan M, Saavedra J M. Expression of angiotensin II AT2 receptors in the rat skin during experimental wound healing. Peptides 1992; 13: 783–786
   PubMed Web of Science ®Google Scholar
• Stoll M, Meffert S, Stroth U, Unger T. Growth or antigrowth: angiotensin and the endothelium. J Hypertension 1995; 13: 1529–1534
   PubMed Web of Science ®Google Scholar
• Clark K L., Robertson M J., Drew G M. Role of angiotensin ATt and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog. Br J Pharmacol 1993; 109: 148–156
   Google Scholar
• Lo M, Liu K-L, Lantelme P, Sassard J. Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Clin Invest 1995; 95: 1394–1397
   Google Scholar
• Naveri L, Stromberg C, Saaverdra J M. Angiotensin II AT2 receptor stimulation extends the upper limit of cerebral blood flow autoregulation: agonist effects of CGP 42112 and PD 123319. J Cereb Blood Flow Metab 1994; 14: 38–44
   PubMedGoogle Scholar
• Clauser E, Curnow K M., Davies E, Conchon S, Teutsch B, Vianello B, Monnot C, Corvol P. Angiotensin II receptors: proteins and gene structures, expression and potential pathological involvements. Eur J Endocrinol 1996; 134(4)403–411
   Google Scholar
• Wong P C., Scott S D., Zaspel A M., Chiu A T., Ardecky R J., Smith R D. Timmer-mans PBMWM. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AIM) and PD 123177 (AII-2). J Pharmacol Exp Ther 1990; 255: 584–592
   PubMed Web of Science ®Google Scholar
• Saavedra J M. Brain and pituitary angiotensin. Endocr Rev 1992; 13: 329–380
   PubMed Web of Science ®Google Scholar
• Brown L, Sernia C. Angiotensin receptors in cardiovascular diseases. Clin Exp Pharmacol Physiol 1994; 21: 811–818
   PubMed Web of Science ®Google Scholar
• Dzau V J., Mukoyama M, Pratt R E. Molecular biology of angiotensin receptors: targets for drug research?. J Hypertension 1994; 12(Suppl 2)S1–S5
   Google Scholar
• Jackson T R., Blair L AC, Marshall J, Godert M, Hanley M R. The mas oncogene encodes an angiotensin receptor. Nature 1988; 335: 437–440
   PubMed Web of Science ®Google Scholar
• Sasaki K, Yamamo Y, Bardhan S, Iwai N, Murray J J., Hasegawa M, Matsuda Y, Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991; 351: 230–233
   PubMed Web of Science ®Google Scholar
• Murphy T J., Alexander R W., Griendling K K., Runge M S., Bernstein K E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351: 233–236
   PubMed Web of Science ®Google Scholar
• Iwai N, Inagami T. Identification of two subtypes in the rat type 1 angiotensin II receptor. FEBS Lett 1992; 298: 257–260
   PubMed Web of Science ®Google Scholar
• Smith R D. Identification of atypical (non-ATI, non-AT2) angiotensin binding sites with high affinity for angiotensin I on IEC-18 rat intestinal epithelial cells. FEBS Lett 1995; 373: 199–202
   Google Scholar
• Takayanagi R, Ohnaka K, Sakai Y, Nakao R, Yanase T, Haji M, Inagami T, Furuta H, Guo D, Nakamuta M, Nawata H. Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor. Biochem Biophys Res Commun 1992; 183: 910–916
   PubMedGoogle Scholar
• Bergsma D, Ellis C, Kumar C, Nuthulaganti P, Kersten H, Elshourbagy N, Griffin E, Stadtel J M., Aiyar N. Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992; 183: 989–995
   PubMed Web of Science ®Google Scholar
• Curnow K M., Pascoe L, Davies E, White P C., Corvol P, Clauser E. Alternatively spliced human type 1 angiotensin II receptor mRNAs are translated at different efficiencies and encode two receptor isoforms. Mol Endocrinol 1995; 9(9)1250–1262
   Google Scholar
• Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt R E., Dzau V J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993; 268: 24539–24542
   PubMed Web of Science ®Google Scholar
• Nahmias C, Cazaubon S M., Briend-Sutren M M., Lazard D, Villageois P, Strosberg A D. Angiotensin II AT2 receptors are functionally coupled to protein tyrosine dephosphorylation in N1E-115 neuroblastoma cells. Biochem J 1995; 306(1)87–92
   Google Scholar
• Brunner H R., Gavras H, Laragh J H., Keenan R. Hypertension in man. Exposure of the renin and angiotensin components using angiotensin II blockade. Circ Res 1974; 35: 1–35; 1–47
   Google Scholar
• Hollenberg N K., Williams G H., Burger B, Ishikawa I, Adams D F. Blockade and stimulation of renal adrenal and vascular angiotensin II receptors in normal man. J Clin Invest 1976; 57: 39–46
   PubMed Web of Science ®Google Scholar
• Yoshiyasu F, Shoji K, Kohei N. Hypotensive imidazole-5-acetic acid derivatives. Takeda Chemical Industries, Ltd. 1982; US4355040
   Google Scholar
• Yoshiyasu F, Shoji K, Kohei N. Imidazole-5-acetic acid derivatives, their production and use. Takeda Chemical Industries, Ltd. 1982; EU0028834
   Google Scholar
• Wong P C., Chiu A T., Price W A., Thoolen M JMC, Carini D J., Johnson A L., Taber R I. Timmermans PBMWM. Non-peptide angiotensin II receptor antagonists. I. Pharmacological characterisation of 2-n-butyl-4-chloro-l-(2-chlorobenzyl) imidazole-5-acetic acid, sodium salt (S-8307). J Pharmacol Exp Ther 1988; 247: 1–7
   PubMed Web of Science ®Google Scholar
• Chiu A T., Carini D J., Johnson A L., McCall D E., Price W A., Thoolen M JMC, Wong P C., Taber R I. Timmermans PBMWM. Non-peptide angiotensin II receptor antagonists. II. Pharmacology of S-8308. Eur J Pharmacol 1988; 157: 13–21
   PubMed Web of Science ®Google Scholar
• Duncia J V., Chiu A T., Carini D J., Gregory G B., Johnson A L., Price W A., Wells G J., Wong P C., Calabrese J C. Timmermans PBMWM. The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J Med Chem 1990; 33: 1312–1329
   PubMed Web of Science ®Google Scholar
• Chiu A T., Duncia J V., McCall D E., Wong P C., Price W A., Thoolen M JMC, Carini D J., Johnson A L. Timmermans PBMWM. Non-peptide angiotensin II receptor antagonists. III. Structure-function studies. J Pharmacol Exp Ther 1989; 250: 867–874
   PubMed Web of Science ®Google Scholar
• Wong P C., Price W A., Chiu A T., Thoolen M JMC, Duncia J V., Johnson A L. Timmermans PBMWM. Non-peptide angiotensin II receptor antagonists. IV. Hypertension 1989; 13: 489–497
   PubMedGoogle Scholar
• Duncia J V., Carini D J., Chiu A T., Johnson A L., Price W A., Wong P C., Wexler R R. Timmermans PBMWM. The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med Res Rev 1992; 12: 149–191
   PubMed Web of Science ®Google Scholar
• Wong P C., Price W A., Chiu A T., Thoolen M JMC, Duncia J V., Carini D J., Wexler R R., Johnson A L. Timmermans PBMWM. Non-peptide angiotensin II receptor antagonists. IX. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255(1)211–217
   PubMed Web of Science ®Google Scholar
• Wong P C., Price W A., Chiu A T., Thoolen M JMC, Duncia J V., Carini D J., Wexler R R., Johnson A L. Timmermans PBMWM. Non-peptide angiotensin II receptor antagonists. X. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension 1990; 15: 459–468
   PubMed Web of Science ®Google Scholar
• Li X C., Widdop R E. Angiotensin type I antagonists CV-1 1974 and EXP 3174 cause selective renal vasodilatation in conscious spontaneously hypertensive rats. Clin Sci 1996; 91(2)147–154
   Google Scholar
• Muller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H. Angiotensin II receptor blockade with single doses of valsartan, in healthy normotensive subjects. Eur J Pharmacol 1994; 47(3)231–245
   Google Scholar
• Bulhmayer P, Furet P, Criscione L, de Gasparo M, Whitebread S, Schmidlin T, Lattmann R, Wood Valsartan J. a potent orally active angiotensin II antagonist developed from the structurally new amino acid series. Bioorg Med Chem Lett 1994; 4: 29–34
   Google Scholar
• Criscione L, de Gasparo M, Bulhmayer P, Whitebread S, Ramjoue H, Wood J. Pharmacological profile of valsartan a potent orally active nonpeptide antagonist of the angiotensin II ATrreceptor subtype. Br J Pharmacol 1993; 110: 761–771
   PubMed Web of Science ®Google Scholar
• Robertson M J., Barnes J C., Drew G M., Clark K L., Marshall F H., Michel A, Middlemiss D, Ross B C., Scopes D, Dowle M D. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT receptor antagonist. Br J Pharmacol 1992; 107: 1173–1180
   PubMed Web of Science ®Google Scholar
• Brooks D P., Fredrickson T A., Weinstock J, Ruffolo R R., Edwards R M., Gellai M. Antihypertensive activity of the nonpeptide angiotensin II receptor antagonist, SK&F 108566 in rats and dogs. Naunyn-Schmiederberg's Arch. Pharmacol 1992; 345: 673–678
   Google Scholar
• Inada Y, Wada T, Yumiko S, Ojima M, Sanada T, Ohtsuki K, Itoh K, Kubo K, Kohara Y, Naka T, Nishikawa K. Anti-hypertensive effect of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (±)-1-(cyclohexyloxycarbonyloxy)ethyl2-ethoxy-1-[[2′-(lH-tetrazol-5-yl)biphenyl-4-yl]methyl]-lH-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. J Pharmacol Exp Ther 1994; 268(3)1540–1547
   Google Scholar
• Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K. Inhibition of rabbit aortic angiotensin II (All) receptor by CV-1 1974 a new nonpeptide All antagonist. Biochem Pharmacol 1993; 46: 311–318
   PubMed Web of Science ®Google Scholar
• Chiu A T., McCall D E., Price W A., Wong P C., Carini D J., Duncia J V., Wexler R R., Yoo S E., Johnson A L. Timmermans PBMWM. Non-peptide angiotensin II receptor antagonists. VII. Cellular and biochemical Pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252(2)711–718
   Google Scholar
• Robertson M J., Wragg A, Clark K L. Modulation of tachyphylaxis to angiotensin II in rabbit isolated aorta by the angiotensin AT, antagonist, losartan. Regul Peptides 1994; 50: 137–145
   PubMed Web of Science ®Google Scholar
• Wong P C. Timmermans PBMWM. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP753. J Pharmacol Exp Ther 1991; 258(1)49–57
   Google Scholar
• Purdy R E., Prins B A., Weber M A., Bakhtiarian A, Smith J R., Kim M K., Nguyen T-HT, Weiler E WJ. Possible novel action of ouabain: allosteric modulation of vascular serotonergic (5-HT2) and angiotensinergic (AT1) receptors. J Pharmacol Exp Ther 1993; 267: 228–237
   PubMed Web of Science ®Google Scholar
• Robertson M J., Dougall I G., Harper D, McKechnie K CW, Leff P. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol Sci 1994; 15: 364–369
   Google Scholar
• Glinka T W., de Laszlo S E., Siegl P KS, Chang R SL, Kivlighn S D., Schorn T S., Faust K A., Chen T B., Zingaro G J., Lotti V J., Greenlee W J. A new class of balanced AT1/AT2 angiotensin II antagonists: quinazolone All antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalities. Bioorg MedChem 1994; 4: 81–86
   Google Scholar
• Chang L L., Ashton W T., Flanagan K L., Chen T-B, O'Malley S S., Zingaro G J., Kivlighn S D., Seigl P KS, Lotti V J., Chang R SL, Greenlee W J. Potent orally active angiotensin II receptor antagonists with equal affinity for human AT] and AT2 subtypes. J Med Chem 1995; 4: 2337–2342
   Google Scholar
• Quan M L., Chiu A T., Ellis C D., Wong P C., Wexler R R. Timmermans PBMWM. Balanced AT1/AT2 receptor antagonists IV. Orally active 5(3-amidopropa-noyl) imidazoles possessing equal affinity for the AT, and AT2 receptors. J Med Chem 1995; 38(15)2938–2945
   Google Scholar
• Kivlighn S D., Huckle W R., Zingaro G J., Rivero R A., Lotti V J., Chang R SL, Schorn T W., Kevin N, Johnson R G., Greenlee W J. Discovery of L-162,313: a nonpeptide that mimics the biological actions of angiotensin II. Am J Physiol 1995; 268: R820–R823
   PubMed Web of Science ®Google Scholar
• Huckle W R., Kivlighn S D., Zingaro G J., Kevin N, Rivero R A., Chang R SL, Greenlee W J., Seigl P KS, Johnson R G. Angiotensin II receptor-mediated activation of phosphoinositide hydrolysis and elevation of mean arterial pressure by a nonpeptide, L163,491. Can J Physiol Pharmacol 1994; 72(Suppl 1)543
   Google Scholar
• Underwood D J., Strader C D., Rivero R, Patchett A A., Greenlee W J., Prendergast K. Structural model of antagonist and agonist binding to the angiotensin II, AT, subtype, G protein coupled receptor. Chem Biol 1994; 1: 211–221
   PubMedGoogle Scholar
• Nirula V, Zheng W, Sothinathan R, Sandberg K. Interaction of biphenylimi-dazole and imidazoleacrylic acid nonpeptide antagonists with valine 108 in TM III of the AT, angiotensin receptor. Br J Pharmacol 1996; 119: 1505–1507
   Google Scholar
• Perlman S, Schambye H T., Rivero R A., Greenlee W J., Hjorth S A., Schwartz T W. Non-peptide angiotensin agonist. Functional and molecular interaction with the AT, receptor. J Biol Chem 1995; 270(4)1493–1496
   Google Scholar
• Ji H J., Leung M, Zhang Y, Catt K J., Sandberg K. Differential requirements for specific binding of nonpeptide and peptide antagonists to the AT, angiotensin receptor. J Biol Chem 1994; 269(24)16533–16536
   PubMed Web of Science ®Google Scholar
• Delacretaz E, Nussberger J, Biollaz J, Waeber B, Brunner H R. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25(1)14–21
   Google Scholar
• Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Waeber B, Brunner H R. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25(4)602–609, part 1
   Google Scholar
• Muller P, Cohen T, deGasparo M, Sioufi A, Raine Poon A, Howard H. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47(3)231–245
   Google Scholar
• Byyny R L. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertension 1995; 13(Suppl 1)S29–S33
   Google Scholar
• Townsend R, Haggert B, Liss C, Edelman J M. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 1995; 17(5)911–923
   Google Scholar
• Holwerda N J., Fogari R, Angeli P, Porcellati C, Hereng C, Oddou P, Stock R, Heath F, Bodin. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertension 1996; 14(9)1147–1151
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Lefebvre J, Nahkle G, Faison E P., Snavely D B., Nelson E B. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled trial. J Hypertension 1994; 12(Suppl 2)S49–S53
   Google Scholar
• Linz W, Wiener G, Gohlke P, Unger T, Scholkens B A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47(l)25–49
   Google Scholar
• Ramsay L E., Yeo W W. ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group. J Hum Hypertension 1995; 9(Suppl 5)S51–54
   Google Scholar
• Waeber B, Brunner H R. Angiotensin II antagonists: a new class of antihypertensive agent. Br J Clin Pract 1996; 50(5)265–268
   Google Scholar
• Goldberg A, Dunlay M, Sweet C. Safety and tolerability of losartan compared with atenolol, felopdipine and ACE-inhibitors. J Hypertension 1995; 13(Suppl 1)S77–S88
   Google Scholar
• Van der Meiracker A H., Admiraal P JJ, Janssen J A., Kroodsma J M., de Ronde W AM, Boomsma F, Sissmann J, Blankestijn P J., Mulder P GM, Manin't Veld A J., Schalekamp M ADH. Hemodynamic and biochemical effects of the AT, receptor antagonist, irbesartan, in hypertension. Hypertension 1995; 25(1)22–29
   Google Scholar
• Klamerus K J., Vadiei K, Burghart P, Neefe D L., Zimmerman J J. Ascending, single-dose, safety, tolerance and pharmacokinetics (PK) of 5,8-dihydro-2,4-dimethyl-8-[2′-(1H-tetrazol-5-yl) [1,1′-biphenyl]-4-yl) methyl] pyrido[2,3-d]pyrimidin-7(6H)-one (ANA-756). Clin Pharmacol Ther 1995; 57(2)203, (PIII-35)
   Google Scholar
• Su C AFP, van Heiningen P NM, van Lier J J., de Bruin H, Kirchgassler K U., Cornelissen P JG, Jonkman J HG. Pharmacodynamics of the All antagonist BIBR0277SE. Clin Pharmacol Ther 1994; 55: 205, (PIII-93)
   Google Scholar
• Urata H, Kinoshita A, Misono K S., Bumpus F M., Hussain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human chymase. J Biol Chem 1990; 265: 22348–22357
   PubMed Web of Science ®Google Scholar
• Miura S, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M, Tanaka H, Shindo M, Arakawa K. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertension 1994; 12: 1177–1181
   Google Scholar
• Anderson I K., Polley J S., Hilditch A, Drew G M. Inhibition of the antihypertensive effect of enalapril and the angiotensin AT] receptor antagonist, GR138950, by Nω-nitro-L-arginine methyl ester in conscious renal hypertensive rats. Br J Pharmacol 1995; 114(Proc Suppl)172P
   Google Scholar
• Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope L M., Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995; 26: 236–243
   PubMed Web of Science ®Google Scholar
• Kagoshima T, Masuda J, Sutani T, Sakaguchi Y, Tsuchihashi M, Tsuruta S, Iwano M, Dohi K, Nakamura Y, Konishi N. Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. Blood Pressure 1994; 5(Suppl)89–93
   Google Scholar
• Nishikimi T, Yamagishi H, Takeuchi K, Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in hypertensive rat. Cardiovasc Res 1995; 29(6)856–861
   Google Scholar
• Furukawa Y, Matsumori A, Hirozane T, Sasayama S. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation 1996; 93(2)333–339
   Google Scholar
• Kino H, Hama J, Takenaka T, Sugimura K, Kamoi K, Shimada S, Yamamoto Y, Nagata S, Kai T, Horiuchi M, Katori R. Effect of an angiotensin II receptor antagonist, TCV-116, on neointimal formation following balloon injury in the SHR carotid artery. Clin Exp Pharmacol Physiol 1995; 22(Suppl 1)S360–S362
   Google Scholar
• Matsumori A, Kawai T, Sugimoto T. Study of the efficacy and safety of TCV-116, an angiotensin II receptor antagonist for chronic heart failure. Jpn Circ J 1995; 59(Suppl 1)619, (abstract)
   Google Scholar
• Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation 1995; 91(3)691–697
   Google Scholar
• Pitt B, Segal R, Martinez F A., Meurers G, Cowley A J., Thomas I, Deedwania P C., Ney D E., Snavely D B., Chang P I. on behalf of the ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–752
   PubMed Web of Science ®Google Scholar